Home / Publications / Highlights of our experience in Biotech

Highlights of our experience in Biotech

  • Roslin Biomed (the “Dolly the Sheep” company) through its lifecycle and on its acquisition by Geron Corp.
  • hVIVO plc on PrEP Biopharm Limited’s licencing arrangements to enable PrEP to develop and commercialise a prophylactic compound on a worldwide basis and the associated £14 million investment into PrEP. Other investors included Johnson & Johnson Innovation.
  • MedAnnex Limited/ Oncobiopharm Limited on separate complex development and licence agreements with a Chinese CRO for the further development of MedAnnex's annexuzlimab product for auto immune disease and Oncobiopharm’s monoclonal antibody Tensinomab anti-cancer product and thereafter commercial exploitation of the products in China.
  • University of Glasgow on the first round of investment into its spin out company, Cronin3D Limited, and subsequently on the acquisition of Cronin3D in a reverse takeover of Oxaco plc and £3.3m placing.
  • The Francis Crick Institute on the transfer of research activities and associated assets from the Medical Research Council and Cancer Research UK.
  • Wellcome Trust on its first euro-denominated bond issue, which raised EUR 400m for its important medical research work as one of the world’s largest charitable foundations.
  • UCL Business on the investment of $20m by Kadmon Therapeutics (now MeiraGTx) into Athena Vision, a spin out company for research into gene therapy in respect of certain ocular conditions.
  • Bloodpharma (a multi-party collaboration involving funding from both the Wellcome Trust and the Scottish Funding Council and aimed at developing technology to produce red blood cells on an industrial scale) on a review its complex contractual arrangements. We also advised on the interaction between those documents and the funding arrangements and associated contractual documentation for a later phase of the project.
  • A biotechnology client on a third party's opposition to its patent for high affinity humanised monoclonal antibodies and prospects of success.
  • Three universities in their cornerstone investment in the Rock Spring Ventures Fund (now Epidarex Capital), a £50m venture capital fund focusing on early-stage Lifesciences and health technology companies.